FAKTOR-OPTIONSSCHEIN - GENMAB | Real-time Bid/Ask 09:18:43 17/06/2024 BST | ||
| 16.7 EUR / 16.84 EUR | +6.01% |
|
| Current month | +31.72% | ||
| 1 month | +49.10% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 17/06/24 | 16.33 | +3.22% |
| 14/06/24 | 15.82 | +1.15% |
| 13/06/24 | 15.64 | +1.69% |
| 12/06/24 | 15.38 | +13.67% |
| 11/06/24 | 13.53 | +8.85% |
Delayed Quote Börse Stuttgart
Last update June 17, 2024 at 07:40 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | Morgan Stanley |
| WKN | MG1KCG |
| ISIN | DE000MG1KCG7 |
| Date issued | 03/04/2024 |
| Strike | 2,199 kr |
| Maturity | Unlimited |
| Parity | 3.13 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.33 € |
|---|---|
| Lowest since issue | 9.28 € |
| Spread | 0.14 € |
| Spread % | 0.85% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,832
DKK
Average target price
2,464
DKK
Spread / Average Target
+34.46%
- Stock Market
- Certificates
- Certificat
